Hormone therapy and cancer risks in transgender people: a systematic review.

IF 2.5 Q1 Multidisciplinary Epidemiologia e Servicos de Saude Pub Date : 2025-01-10 eCollection Date: 2025-01-01 DOI:10.1590/S2237-96222024v33e2024319.especial.en

Liza Yurie Teruya Uchimura, Tatiana Yonekura, Mabel Fernandes Figueiró, Jeane Roza Quintans, Patrícia Freire, Fernando Henrique de Albuquerque Maia

{"title":"Hormone therapy and cancer risks in transgender people: a systematic review.","authors":"Liza Yurie Teruya Uchimura, Tatiana Yonekura, Mabel Fernandes Figueiró, Jeane Roza Quintans, Patrícia Freire, Fernando Henrique de Albuquerque Maia","doi":"10.1590/S2237-96222024v33e2024319.especial.en","DOIUrl":null,"url":null,"abstract":"Objective: To identify the available evidence on the risk of developing cancer in transgender people undergoing hormone therapy.Methods: This was a rapid systematic review conducted in the PubMed, Embase, Virtual Health Library, Cochrane Library and Epistemonikos databases. Screening and data extraction were performed by independent reviewers using the Rayyan platform. Data extraction was carried out by 3 independent reviewers. We used the Joanna Briggs Institute checklists specific to cohort and case-control studies to assess the methodological quality of the included studies.Results: Five studies were included, 4 cohort studies and 1 case-control. The risk of transgender people developing cancer while on hormone therapy was identified by 2 studies and not identified in 3 studies.Conclusion: Despite studies with large sample sizes and rigorous selection criteria, the literature does not present a consensus on the association between hormone therapy and the development of cancer in transgender people.","PeriodicalId":51473,"journal":{"name":"Epidemiologia e Servicos de Saude","volume":"33 spe1","pages":"e2024319"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734654/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologia e Servicos de Saude","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S2237-96222024v33e2024319.especial.en","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Multidisciplinary","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To identify the available evidence on the risk of developing cancer in transgender people undergoing hormone therapy.

Methods: This was a rapid systematic review conducted in the PubMed, Embase, Virtual Health Library, Cochrane Library and Epistemonikos databases. Screening and data extraction were performed by independent reviewers using the Rayyan platform. Data extraction was carried out by 3 independent reviewers. We used the Joanna Briggs Institute checklists specific to cohort and case-control studies to assess the methodological quality of the included studies.

Results: Five studies were included, 4 cohort studies and 1 case-control. The risk of transgender people developing cancer while on hormone therapy was identified by 2 studies and not identified in 3 studies.

Conclusion: Despite studies with large sample sizes and rigorous selection criteria, the literature does not present a consensus on the association between hormone therapy and the development of cancer in transgender people.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

变性人的激素治疗和癌症风险：一项系统综述。

目的：确定接受激素治疗的变性人患癌风险的现有证据。方法：对PubMed、Embase、Virtual Health Library、Cochrane Library和Epistemonikos数据库进行快速系统评价。筛选和数据提取由独立审稿人使用Rayyan平台进行。数据提取由3名独立审稿人进行。我们使用乔安娜布里格斯研究所针对队列研究和病例对照研究的检查表来评估纳入研究的方法学质量。结果：纳入5项研究，4项队列研究，1项病例对照。变性人在接受激素治疗时患癌症的风险在两项研究中被确认而在三项研究中没有被确认。结论：尽管研究样本量大，选择标准严格，但文献并未就激素治疗与变性人癌症发展之间的关系达成共识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊